This clinical trial is focused on studying a disease called Classical Hodgkin Lymphoma, which is a type of cancer that affects the lymphatic system, a part of the immune system. The trial will explore the effectiveness of a treatment involving a medication called Brentuximab Vedotin. This medication is an antibody-drug conjugate, which means it combines an antibody with a drug to specifically target and kill cancer cells. The study will also involve other medications, including Dacarbazine, Doxorubicin Hydrochloride, and Nivolumab. These medications are used in combination to enhance the treatment’s effectiveness.

The purpose of the study is to assess how well the treatment works in achieving a complete response, which means the disappearance of all signs of cancer in the body, in patients who have not been treated before. Participants in the study will receive the treatment through intravenous infusion, which means the medication is given directly into a vein. The study will be conducted over several parts, and each part will have a specific focus on different aspects of the treatment and its effects on the disease.

Throughout the study, participants will be monitored for any side effects or changes in their condition. The study aims to gather information on the safety and effectiveness of the treatment, as well as to understand how the disease responds to the combination of medications. The trial is expected to continue until 2027, providing valuable insights into the treatment of Classical Hodgkin Lymphoma.